0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global and United States Neurodegenerative Drugs Market Insights, Forecast to 2027
Published Date: September 2021
|
Report Code: QYRE-Auto-26D6533
Home | Market Reports | Business & Industrial | Pharmaceuticals & Biotech
Global and United States Neurodegenerative Drugs Market Insights Forecast to 2027

Global and United States Neurodegenerative Drugs Market Insights, Forecast to 2027

Code: QYRE-Auto-26D6533
Report
September 2021
152 Pages
QYResearch
Region: Global,
Description
Table of Content
Tables & Figures
Neurodegenerative Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Neurodegenerative Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For United States market, this report focuses on the Neurodegenerative Drugs market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in United States.

Segment by Type

NMDA
SSRIs
Dopamine Inhibitors

Segment by Application

Parkinson’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease

BY REGION

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

BY COMPANY

Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline
Livzon Pharmaceutical
Haisco Pharmaceutical
Jingxin Pharmaceutical
Dongcheng Biochemicals
Hisun Pharmaceutical
Luye Pharma
Ark Pharmaceutical
Kanghong Pharmaceutical
Huahai Pharmaceutical
BORA PHARMACEUTICALS
1 Study Coverage
1.1 Neurodegenerative Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Neurodegenerative Drugs Market Size Growth Rate by Type
1.2.2 NMDA
1.2.3 SSRIs
1.2.4 Dopamine Inhibitors
1.3 Market by Application
1.3.1 Global Neurodegenerative Drugs Market Size Growth Rate by Application
1.3.2 Parkinson’s Disease
1.3.3 Huntington Disease
1.3.4 Amyotrophic Lateral Sclerosis
1.3.5 Alzheimer’s Disease
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Neurodegenerative Drugs Market Size, Estimates and Forecasts
2.1.1 Global Neurodegenerative Drugs Revenue 2016-2027
2.1.2 Global Neurodegenerative Drugs Sales 2016-2027
2.2 Global Neurodegenerative Drugs, Market Size by Region: 2016 VS 2021 VS 2027
2.3 Neurodegenerative Drugs Historical Market Size by Region (2016-2021)
2.3.1 Global Neurodegenerative Drugs Retrospective Market Scenario in Sales by Region: 2016-2021
2.3.2 Global Neurodegenerative Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021
2.4 Neurodegenerative Drugs Market Estimates and Projections by Region (2022-2027)
2.4.1 Global Neurodegenerative Drugs Sales Forecast by Region (2022-2027)
2.4.2 Global Neurodegenerative Drugs Revenue Forecast by Region (2022-2027)
3 Global Neurodegenerative Drugs Competitor Landscape by Players
3.1 Global Top Neurodegenerative Drugs Manufacturers by Sales
3.1.1 Global Neurodegenerative Drugs Sales by Manufacturer (2016-2021)
3.1.2 Global Neurodegenerative Drugs Sales Market Share by Manufacturer (2016-2021)
3.2 Global Top Neurodegenerative Drugs Manufacturers by Revenue
3.2.1 Key Neurodegenerative Drugs Manufacturers Covered: Ranking by Revenue
3.2.2 Global Neurodegenerative Drugs Revenue by Manufacturers (2016-2021)
3.2.3 Global Neurodegenerative Drugs Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Neurodegenerative Drugs Market Concentration Ratio (CR5 and HHI) (2016-2021)
3.2.5 Global Top 10 and Top 5 Companies by Neurodegenerative Drugs Revenue in 2020
3.2.6 Global Neurodegenerative Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Neurodegenerative Drugs Price by Manufacturers
3.4 Global Neurodegenerative Drugs Manufacturing Base Distribution, Product Types
3.4.1 Neurodegenerative Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Neurodegenerative Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Neurodegenerative Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2016-2027)
4.1 Global Neurodegenerative Drugs Market Size by Type (2016-2021)
4.1.1 Global Neurodegenerative Drugs Sales by Type (2016-2021)
4.1.2 Global Neurodegenerative Drugs Revenue by Type (2016-2021)
4.1.3 Neurodegenerative Drugs Average Selling Price (ASP) by Type (2016-2021)
4.2 Global Neurodegenerative Drugs Market Size Forecast by Type (2022-2027)
4.2.1 Global Neurodegenerative Drugs Sales Forecast by Type (2022-2027)
4.2.2 Global Neurodegenerative Drugs Revenue Forecast by Type (2022-2027)
4.2.3 Neurodegenerative Drugs Average Selling Price (ASP) Forecast by Type (2022-2027)
5 Breakdown Data by Application (2016-2027)
5.1 Global Neurodegenerative Drugs Market Size by Application (2016-2021)
5.1.1 Global Neurodegenerative Drugs Sales by Application (2016-2021)
5.1.2 Global Neurodegenerative Drugs Revenue by Application (2016-2021)
5.1.3 Neurodegenerative Drugs Price by Application (2016-2021)
5.2 Neurodegenerative Drugs Market Size Forecast by Application (2022-2027)
5.2.1 Global Neurodegenerative Drugs Sales Forecast by Application (2022-2027)
5.2.2 Global Neurodegenerative Drugs Revenue Forecast by Application (2022-2027)
5.2.3 Global Neurodegenerative Drugs Price Forecast by Application (2022-2027)
6 United States by Players, Type and Application
6.1 United States Neurodegenerative Drugs Market Size YoY Growth 2016-2027
6.1.1 United States Neurodegenerative Drugs Sales YoY Growth 2016-2027
6.1.2 United States Neurodegenerative Drugs Revenue YoY Growth 2016-2027
6.1.3 United States Neurodegenerative Drugs Market Share in Global Market 2016-2027
6.2 United States Neurodegenerative Drugs Market Size by Players (International and Local Players)
6.2.1 United States Top Neurodegenerative Drugs Players by Sales (2016-2021)
6.2.2 United States Top Neurodegenerative Drugs Players by Revenue (2016-2021)
6.3 United States Neurodegenerative Drugs Historic Market Review by Type (2016-2021)
6.3.1 United States Neurodegenerative Drugs Sales Market Share by Type (2016-2021)
6.3.2 United States Neurodegenerative Drugs Revenue Market Share by Type (2016-2021)
6.3.3 United States Neurodegenerative Drugs Price by Type (2016-2021)
6.4 United States Neurodegenerative Drugs Market Estimates and Forecasts by Type (2022-2027)
6.4.1 United States Neurodegenerative Drugs Sales Forecast by Type (2022-2027)
6.4.2 United States Neurodegenerative Drugs Revenue Forecast by Type (2022-2027)
6.4.3 United States Neurodegenerative Drugs Price Forecast by Type (2022-2027)
6.5 United States Neurodegenerative Drugs Historic Market Review by Application (2016-2021)
6.5.1 United States Neurodegenerative Drugs Sales Market Share by Application (2016-2021)
6.5.2 United States Neurodegenerative Drugs Revenue Market Share by Application (2016-2021)
6.5.3 United States Neurodegenerative Drugs Price by Application (2016-2021)
6.6 United States Neurodegenerative Drugs Market Estimates and Forecasts by Application (2022-2027)
6.6.1 United States Neurodegenerative Drugs Sales Forecast by Application (2022-2027)
6.6.2 United States Neurodegenerative Drugs Revenue Forecast by Application (2022-2027)
6.6.3 United States Neurodegenerative Drugs Price Forecast by Application (2022-2027)
7 North America
7.1 North America Neurodegenerative Drugs Market Size YoY Growth 2016-2027
7.2 North America Neurodegenerative Drugs Market Facts & Figures by Country
7.2.1 North America Neurodegenerative Drugs Sales by Country (2016-2021)
7.2.2 North America Neurodegenerative Drugs Revenue by Country (2016-2021)
7.2.3 United States
7.2.4 Canada
8 Asia Pacific
8.1 Asia Pacific Neurodegenerative Drugs Market Size YoY Growth 2016-2027
8.2 Asia Pacific Neurodegenerative Drugs Market Facts & Figures by Region
8.2.1 Asia Pacific Neurodegenerative Drugs Sales by Region (2016-2021)
8.2.2 Asia Pacific Neurodegenerative Drugs Revenue by Region (2016-2021)
8.2.3 China
8.2.4 Japan
8.2.5 South Korea
8.2.6 India
8.2.7 Australia
8.2.8 Australia
8.2.9 Indonesia
8.2.10 Thailand
8.2.11 Malaysia
9 Europe
9.1 Europe Neurodegenerative Drugs Market Size YoY Growth 2016-2027
9.2 Europe Neurodegenerative Drugs Market Facts & Figures by Country
9.2.1 Europe Neurodegenerative Drugs Sales by Country (2016-2021)
9.2.2 Europe Neurodegenerative Drugs Revenue by Country (2016-2021)
9.2.3 Germany
9.2.4 France
9.2.5 U.K.
9.2.6 Italy
10 Latin America
10.1 Latin America Neurodegenerative Drugs Market Size YoY Growth 2016-2027
10.2 Latin America Neurodegenerative Drugs Market Facts & Figures by Country
10.2.1 Latin America Neurodegenerative Drugs Sales by Country (2016-2021)
10.2.2 Latin America Neurodegenerative Drugs Revenue by Country (2016-2021)
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Neurodegenerative Drugs Market Size YoY Growth 2016-2027
11.2 Middle East and Africa Neurodegenerative Drugs Market Facts & Figures by Country
11.2.1 Middle East and Africa Neurodegenerative Drugs Sales by Country (2016-2021)
11.2.2 Middle East and Africa Neurodegenerative Drugs Revenue by Country (2016-2021)
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 UAE
12 Company Profiles
12.1 Novartis
12.1.1 Novartis Corporation Information
12.1.2 Novartis Description and Business Overview
12.1.3 Novartis Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Novartis Neurodegenerative Drugs Products Offered
12.1.5 Novartis Recent Development
12.2 Pfizer
12.2.1 Pfizer Corporation Information
12.2.2 Pfizer Description and Business Overview
12.2.3 Pfizer Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Pfizer Neurodegenerative Drugs Products Offered
12.2.5 Pfizer Recent Development
12.3 Merck Serono
12.3.1 Merck Serono Corporation Information
12.3.2 Merck Serono Description and Business Overview
12.3.3 Merck Serono Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Merck Serono Neurodegenerative Drugs Products Offered
12.3.5 Merck Serono Recent Development
12.4 Biogen Idec
12.4.1 Biogen Idec Corporation Information
12.4.2 Biogen Idec Description and Business Overview
12.4.3 Biogen Idec Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Biogen Idec Neurodegenerative Drugs Products Offered
12.4.5 Biogen Idec Recent Development
12.5 TEVA
12.5.1 TEVA Corporation Information
12.5.2 TEVA Description and Business Overview
12.5.3 TEVA Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
12.5.4 TEVA Neurodegenerative Drugs Products Offered
12.5.5 TEVA Recent Development
12.6 UCB
12.6.1 UCB Corporation Information
12.6.2 UCB Description and Business Overview
12.6.3 UCB Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
12.6.4 UCB Neurodegenerative Drugs Products Offered
12.6.5 UCB Recent Development
12.7 Boehringer Ingelheim
12.7.1 Boehringer Ingelheim Corporation Information
12.7.2 Boehringer Ingelheim Description and Business Overview
12.7.3 Boehringer Ingelheim Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Boehringer Ingelheim Neurodegenerative Drugs Products Offered
12.7.5 Boehringer Ingelheim Recent Development
12.8 Sanofi
12.8.1 Sanofi Corporation Information
12.8.2 Sanofi Description and Business Overview
12.8.3 Sanofi Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Sanofi Neurodegenerative Drugs Products Offered
12.8.5 Sanofi Recent Development
12.9 GlaxoSmithKline
12.9.1 GlaxoSmithKline Corporation Information
12.9.2 GlaxoSmithKline Description and Business Overview
12.9.3 GlaxoSmithKline Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
12.9.4 GlaxoSmithKline Neurodegenerative Drugs Products Offered
12.9.5 GlaxoSmithKline Recent Development
12.10 Livzon Pharmaceutical
12.10.1 Livzon Pharmaceutical Corporation Information
12.10.2 Livzon Pharmaceutical Description and Business Overview
12.10.3 Livzon Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Livzon Pharmaceutical Neurodegenerative Drugs Products Offered
12.10.5 Livzon Pharmaceutical Recent Development
12.11 Novartis
12.11.1 Novartis Corporation Information
12.11.2 Novartis Description and Business Overview
12.11.3 Novartis Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Novartis Neurodegenerative Drugs Products Offered
12.11.5 Novartis Recent Development
12.12 Jingxin Pharmaceutical
12.12.1 Jingxin Pharmaceutical Corporation Information
12.12.2 Jingxin Pharmaceutical Description and Business Overview
12.12.3 Jingxin Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
12.12.4 Jingxin Pharmaceutical Products Offered
12.12.5 Jingxin Pharmaceutical Recent Development
12.13 Dongcheng Biochemicals
12.13.1 Dongcheng Biochemicals Corporation Information
12.13.2 Dongcheng Biochemicals Description and Business Overview
12.13.3 Dongcheng Biochemicals Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
12.13.4 Dongcheng Biochemicals Products Offered
12.13.5 Dongcheng Biochemicals Recent Development
12.14 Hisun Pharmaceutical
12.14.1 Hisun Pharmaceutical Corporation Information
12.14.2 Hisun Pharmaceutical Description and Business Overview
12.14.3 Hisun Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
12.14.4 Hisun Pharmaceutical Products Offered
12.14.5 Hisun Pharmaceutical Recent Development
12.15 Luye Pharma
12.15.1 Luye Pharma Corporation Information
12.15.2 Luye Pharma Description and Business Overview
12.15.3 Luye Pharma Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
12.15.4 Luye Pharma Products Offered
12.15.5 Luye Pharma Recent Development
12.16 Ark Pharmaceutical
12.16.1 Ark Pharmaceutical Corporation Information
12.16.2 Ark Pharmaceutical Description and Business Overview
12.16.3 Ark Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
12.16.4 Ark Pharmaceutical Products Offered
12.16.5 Ark Pharmaceutical Recent Development
12.17 Kanghong Pharmaceutical
12.17.1 Kanghong Pharmaceutical Corporation Information
12.17.2 Kanghong Pharmaceutical Description and Business Overview
12.17.3 Kanghong Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
12.17.4 Kanghong Pharmaceutical Products Offered
12.17.5 Kanghong Pharmaceutical Recent Development
12.18 Huahai Pharmaceutical
12.18.1 Huahai Pharmaceutical Corporation Information
12.18.2 Huahai Pharmaceutical Description and Business Overview
12.18.3 Huahai Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
12.18.4 Huahai Pharmaceutical Products Offered
12.18.5 Huahai Pharmaceutical Recent Development
12.19 BORA PHARMACEUTICALS
12.19.1 BORA PHARMACEUTICALS Corporation Information
12.19.2 BORA PHARMACEUTICALS Description and Business Overview
12.19.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
12.19.4 BORA PHARMACEUTICALS Products Offered
12.19.5 BORA PHARMACEUTICALS Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Neurodegenerative Drugs Industry Trends
13.2 Neurodegenerative Drugs Market Drivers
13.3 Neurodegenerative Drugs Market Challenges
13.4 Neurodegenerative Drugs Market Restraints
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Neurodegenerative Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables
    Table 1. Global Neurodegenerative Drugs Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
    Table 2. Major Manufacturers of NMDA
    Table 3. Major Manufacturers of SSRIs
    Table 4. Major Manufacturers of Dopamine Inhibitors
    Table 5. Global Neurodegenerative Drugs Market Size Growth Rate by Application (2021-2027) & (K Units)
    Table 6. Global Neurodegenerative Drugs Market Size by Region (K Units) & (US$ Million), 2016 VS 2021 VS 2027
    Table 7. Global Neurodegenerative Drugs Sales by Regions (2016-2021) & (K Units)
    Table 8. Global Neurodegenerative Drugs Sales Market Share by Regions (2016-2021)
    Table 9. Global Neurodegenerative Drugs Revenue by Regions (2016-2021) & (US$ Million)
    Table 10. Global Neurodegenerative Drugs Sales Forecast by Region (2022-2027) & (K Units)
    Table 11. Global Neurodegenerative Drugs Sales Market Share Forecast by Region (2022-2027)
    Table 12. Global Neurodegenerative Drugs Revenue Forecast by Region (2022-2027) & (US$ Million)
    Table 13. Global Neurodegenerative Drugs Revenue Market Share Forecast by Region (2022-2027)
    Table 14. Global Neurodegenerative Drugs Sales by Manufacturers (2016-2021) (K Units)
    Table 15. Global Neurodegenerative Drugs Sales Share by Manufacturers (2016-2021)
    Table 16. Ranking of Global Top Neurodegenerative Drugs Manufacturers by Revenue (US$ Million) in 2020
    Table 17. Neurodegenerative Drugs Revenue by Manufacturers (2016-2021) (US$ Million)
    Table 18. Neurodegenerative Drugs Revenue Share by Manufacturers (2016-2021)
    Table 19. Global Neurodegenerative Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) & (2016-2021)
    Table 20. Global Neurodegenerative Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurodegenerative Drugs as of 2020)
    Table 21. Key Manufacturers Neurodegenerative Drugs Price (2016-2021) (US$/Unit)
    Table 22. Neurodegenerative Drugs Manufacturers Manufacturing Base Distribution and Headquarters
    Table 23. Manufacturers Neurodegenerative Drugs Product Type
    Table 24. Date of International Manufacturers Enter into Neurodegenerative Drugs Market
    Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 26. Global Neurodegenerative Drugs Sales by Type (2016-2021) (K Units)
    Table 27. Global Neurodegenerative Drugs Sales Share by Type (2016-2021)
    Table 28. Global Neurodegenerative Drugs Revenue by Type (2016-2021) (US$ Million)
    Table 29. Global Neurodegenerative Drugs Revenue Share by Type (2016-2021)
    Table 30. Neurodegenerative Drugs Average Selling Price (ASP) by Type (2016-2021) & (US$/Unit)
    Table 31. Global Neurodegenerative Drugs Sales Forecast by Type (2022-2027) & (K Units)
    Table 32. Global Neurodegenerative Drugs Sales Market Share Forecast by Type (2022-2027)
    Table 33. Global Neurodegenerative Drugs Revenue Forecast V (2022-2027) & (US$ Million)
    Table 34. Global Neurodegenerative Drugs Revenue Market Share Forecast by Type (2022-2027)
    Table 35. Global Neurodegenerative Drugs Average Selling Price (ASP) Forecast by Type (2022-2027) & (US$/Unit)
    Table 36. Global Neurodegenerative Drugs Sales by Application (2016-2021) (K Units)
    Table 37. Global Neurodegenerative Drugs Sales Share by Application (2016-2021)
    Table 38. Global Neurodegenerative Drugs Revenue by Application (2016-2021) (US$ Million)
    Table 39. Global Neurodegenerative Drugs Revenue Share by Application (2016-2021)
    Table 40. Neurodegenerative Drugs Average Selling Price (ASP) by Application (2016-2021) & (US$/Unit)
    Table 41. Global Neurodegenerative Drugs Sales Forecast by Application (2022-2027) & (K Units)
    Table 42. Global Neurodegenerative Drugs Sales Market Share Forecast by Application (2022-2027)
    Table 43. Global Neurodegenerative Drugs Revenue Forecast by Application (2022-2027) & (US$ Million)
    Table 44. Global Neurodegenerative Drugs Revenue Market Share Forecast by Application (2022-2027)
    Table 45. Global Neurodegenerative Drugs Average Selling Price (ASP) Forecast by Application (2022-2027) & (US$/Unit)
    Table 46. United States Neurodegenerative Drugs Sales (K Units) of Key Companies (2016-2021)
    Table 47. United States Neurodegenerative Drugs Sales Share by Company (2016-2021)
    Table 48. United States Neurodegenerative Drugs Revenue (US$ Million) by Company (2016-2021)
    Table 49. United States Neurodegenerative Drugs Revenue Share by Company (2016-2021)
    Table 50. United States Neurodegenerative Drugs Sales (K Units) by Type (2016-2021)
    Table 51. United States Neurodegenerative Drugs Sales Share by Type (2016-2021)
    Table 52. United States Neurodegenerative Drugs Revenue (US$ Million) Market Share by Type (2016-2021)
    Table 53. United States Neurodegenerative Drugs Price (US$/Unit) by Type (2016-2021)
    Table 54. United States Neurodegenerative Drugs Sales (K Units) by Type (2022-2027)
    Table 55. United States Neurodegenerative Drugs Sales Share by Type (2022-2027)
    Table 56. United States Neurodegenerative Drugs Revenue (US$ Million) Market Share by Type (2022-2027)
    Table 57. United States Neurodegenerative Drugs Revenue Share by Type (2022-2027)
    Table 58. United States Neurodegenerative Drugs Price (US$/Unit) by Type (2022-2027)
    Table 59. United States Neurodegenerative Drugs Sales (K Units) by Application (2016-2021)
    Table 60. United States Neurodegenerative Drugs Sales Share by Application (2016-2021)
    Table 61. United States Neurodegenerative Drugs Revenue (US$ Million) Market Share by Application (2016-2021)
    Table 62. United States Neurodegenerative Drugs Price (US$/Unit) by Application (2016-2021)
    Table 63. United States Neurodegenerative Drugs Sales (K Units) by Application (2022-2027)
    Table 64. United States Neurodegenerative Drugs Sales Share by Application (2022-2027)
    Table 65. United States Neurodegenerative Drugs Revenue (US$ Million) Market Share by Application (2022-2027)
    Table 66. United States Neurodegenerative Drugs Revenue Share by Application (2022-2027)
    Table 67. United States Neurodegenerative Drugs Price (US$/Unit) by Application (2022-2027)
    Table 68. North America Neurodegenerative Drugs Sales by Country (2016-2021) & (K Units)
    Table 69. North America Neurodegenerative Drugs Sales Market Share by Country (2016-2021)
    Table 70. North America Neurodegenerative Drugs Revenue by Country (2016-2021) & (US$ Million)
    Table 71. North America Neurodegenerative Drugs Revenue Market Share by Country (2016-2021)
    Table 72. Asia Pacific Neurodegenerative Drugs Sales by Region (2016-2021) & (K Units)
    Table 73. Asia Pacific Neurodegenerative Drugs Sales Market Share by Region (2016-2021)
    Table 74. Asia Pacific Neurodegenerative Drugs Revenue by Region (2016-2021) & (US$ Million)
    Table 75. Asia Pacific Neurodegenerative Drugs Revenue Market Share by Region (2016-2021)
    Table 76. Europe Neurodegenerative Drugs Sales by Country (2016-2021) & (K Units)
    Table 77. Europe Neurodegenerative Drugs Sales Market Share by Country (2016-2021)
    Table 78. Europe Neurodegenerative Drugs Revenue by Country (2016-2021) & (US$ Million)
    Table 79. Europe Neurodegenerative Drugs Revenue Market Share by Country (2016-2021)
    Table 80. Latin America Neurodegenerative Drugs Sales by Country (2016-2021) & (K Units)
    Table 81. Latin America Neurodegenerative Drugs Sales Market Share by Country (2016-2021)
    Table 82. Latin Americaa Neurodegenerative Drugs Revenue by Country (2016-2021) & (US$ Million)
    Table 83. Latin America Neurodegenerative Drugs Revenue Market Share by Country (2016-2021)
    Table 84. Middle East and Africa Neurodegenerative Drugs Sales by Country (2016-2021) & (K Units)
    Table 85. Middle East and Africa Neurodegenerative Drugs Sales Market Share by Country (2016-2021)
    Table 86. Middle East and Africa Neurodegenerative Drugs Revenue by Country (2016-2021) & (US$ Million)
    Table 87. Middle East and Africa Neurodegenerative Drugs Revenue Market Share by Country (2016-2021)
    Table 88. Novartis Corporation Information
    Table 89. Novartis Description and Business Overview
    Table 90. Novartis Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 91. Novartis Neurodegenerative Drugs Product
    Table 92. Novartis Recent Development
    Table 93. Pfizer Corporation Information
    Table 94. Pfizer Description and Business Overview
    Table 95. Pfizer Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 96. Pfizer Product
    Table 97. Pfizer Recent Development
    Table 98. Merck Serono Corporation Information
    Table 99. Merck Serono Description and Business Overview
    Table 100. Merck Serono Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 101. Merck Serono Product
    Table 102. Merck Serono Recent Development
    Table 103. Biogen Idec Corporation Information
    Table 104. Biogen Idec Description and Business Overview
    Table 105. Biogen Idec Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 106. Biogen Idec Product
    Table 107. Biogen Idec Recent Development
    Table 108. TEVA Corporation Information
    Table 109. TEVA Description and Business Overview
    Table 110. TEVA Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 111. TEVA Product
    Table 112. TEVA Recent Development
    Table 113. UCB Corporation Information
    Table 114. UCB Description and Business Overview
    Table 115. UCB Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 116. UCB Product
    Table 117. UCB Recent Development
    Table 118. Boehringer Ingelheim Corporation Information
    Table 119. Boehringer Ingelheim Description and Business Overview
    Table 120. Boehringer Ingelheim Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 121. Boehringer Ingelheim Product
    Table 122. Boehringer Ingelheim Recent Development
    Table 123. Sanofi Corporation Information
    Table 124. Sanofi Description and Business Overview
    Table 125. Sanofi Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 126. Sanofi Product
    Table 127. Sanofi Recent Development
    Table 128. GlaxoSmithKline Corporation Information
    Table 129. GlaxoSmithKline Description and Business Overview
    Table 130. GlaxoSmithKline Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 131. GlaxoSmithKline Product
    Table 132. GlaxoSmithKline Recent Development
    Table 133. Livzon Pharmaceutical Corporation Information
    Table 134. Livzon Pharmaceutical Description and Business Overview
    Table 135. Livzon Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 136. Livzon Pharmaceutical Product
    Table 137. Livzon Pharmaceutical Recent Development
    Table 138. Haisco Pharmaceutical Corporation Information
    Table 139. Haisco Pharmaceutical Description and Business Overview
    Table 140. Haisco Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 141. Haisco Pharmaceutical Product
    Table 142. Haisco Pharmaceutical Recent Development
    Table 143. Jingxin Pharmaceutical Corporation Information
    Table 144. Jingxin Pharmaceutical Description and Business Overview
    Table 145. Jingxin Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 146. Jingxin Pharmaceutical Product
    Table 147. Jingxin Pharmaceutical Recent Development
    Table 148. Dongcheng Biochemicals Corporation Information
    Table 149. Dongcheng Biochemicals Description and Business Overview
    Table 150. Dongcheng Biochemicals Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 151. Dongcheng Biochemicals Product
    Table 152. Dongcheng Biochemicals Recent Development
    Table 153. Hisun Pharmaceutical Corporation Information
    Table 154. Hisun Pharmaceutical Description and Business Overview
    Table 155. Hisun Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 156. Hisun Pharmaceutical Product
    Table 157. Hisun Pharmaceutical Recent Development
    Table 158. Luye Pharma Corporation Information
    Table 159. Luye Pharma Description and Business Overview
    Table 160. Luye Pharma Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 161. Luye Pharma Product
    Table 162. Luye Pharma Recent Development
    Table 163. Ark Pharmaceutical Corporation Information
    Table 164. Ark Pharmaceutical Description and Business Overview
    Table 165. Ark Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 166. Ark Pharmaceutical Product
    Table 167. Ark Pharmaceutical Recent Development
    Table 168. Kanghong Pharmaceutical Corporation Information
    Table 169. Kanghong Pharmaceutical Description and Business Overview
    Table 170. Kanghong Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 171. Kanghong Pharmaceutical Product
    Table 172. Kanghong Pharmaceutical Recent Development
    Table 173. Huahai Pharmaceutical Corporation Information
    Table 174. Huahai Pharmaceutical Description and Business Overview
    Table 175. Huahai Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 176. Huahai Pharmaceutical Product
    Table 177. Huahai Pharmaceutical Recent Development
    Table 178. BORA PHARMACEUTICALS Corporation Information
    Table 179. BORA PHARMACEUTICALS Description and Business Overview
    Table 180. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
    Table 181. BORA PHARMACEUTICALS Product
    Table 182. BORA PHARMACEUTICALS Recent Development
    Table 183. Neurodegenerative Drugs Market Trends
    Table 184. Neurodegenerative Drugs Market Drivers
    Table 185. Neurodegenerative Drugs Market Challenges
    Table 186. Neurodegenerative Drugs Market Restraints
    Table 187. Neurodegenerative Drugs Customers List
    Table 188. Neurodegenerative Drugs Distributors List
    Table 189. Research Programs/Design for This Report
    Table 190. Key Data Information from Secondary Sources
    Table 191. Key Data Information from Primary Sources
List of Figures
    Figure 1. Neurodegenerative Drugs Product Picture
    Figure 2. Global Neurodegenerative Drugs Sales Market Share by Type in 2020 & 2027
    Figure 3. NMDA Product Picture
    Figure 4. SSRIs Product Picture
    Figure 5. Dopamine Inhibitors Product Picture
    Figure 6. Global Neurodegenerative Drugs Sales Market Share by Application in 2020 & 2027
    Figure 7. Parkinson’s Disease
    Figure 8. Huntington Disease
    Figure 9. Amyotrophic Lateral Sclerosis
    Figure 10. Alzheimer’s Disease
    Figure 11. Neurodegenerative Drugs Report Years Considered
    Figure 12. Global Neurodegenerative Drugs Market Size, (US$ Million), 2016 VS 2021 VS 2027
    Figure 13. Global Neurodegenerative Drugs Market Size 2016-2027 (US$ Million)
    Figure 14. Global Neurodegenerative Drugs Sales 2016-2027 (K Units)
    Figure 15. Global Neurodegenerative Drugs Market Size Market Share by Region: 2021 Versus 2027
    Figure 16. Global Neurodegenerative Drugs Sales Market Share by Region (2016-2021)
    Figure 17. Global Neurodegenerative Drugs Sales Market Share by Region in 2020
    Figure 18. Global Neurodegenerative Drugs Revenue Market Share by Region (2016-2021)
    Figure 19. Global Neurodegenerative Drugs Revenue Market Share by Region in 2020
    Figure 20. Global Neurodegenerative Drugs Sales Share by Manufacturer in 2020
    Figure 21. The Top 10 and 5 Players Market Share by Neurodegenerative Drugs Revenue in 2020
    Figure 22. Neurodegenerative Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
    Figure 23. Global Neurodegenerative Drugs Sales Market Share by Type (2016-2021)
    Figure 24. Global Neurodegenerative Drugs Sales Market Share by Type in 2020
    Figure 25. Global Neurodegenerative Drugs Revenue Market Share by Type (2016-2021)
    Figure 26. Global Neurodegenerative Drugs Revenue Market Share by Type in 2020
    Figure 27. Global Neurodegenerative Drugs Sales Market Share by Application (2016-2021)
    Figure 28. Global Neurodegenerative Drugs Sales Market Share by Application in 2020
    Figure 29. Global Neurodegenerative Drugs Revenue Market Share by Application (2016-2021)
    Figure 30. Global Neurodegenerative Drugs Revenue Market Share by Application in 2020
    Figure 31. United States Neurodegenerative Drugs Sales Growth Rate 2016-2027 (K Units)
    Figure 32. United States Neurodegenerative Drugs Revenue Growth Rate 2016-2027 (US$ Million)
    Figure 33. United States Neurodegenerative Drugs Market Share in Global Market 2016-2027
    Figure 34. United States 5 and 10 Largest Neurodegenerative Drugs Players Market Share by Revenue in Neurodegenerative Drugs in 2020
    Figure 35. United States Neurodegenerative Drugs Revenue Share by Type (2016-2021)
    Figure 36. United States Neurodegenerative Drugs Revenue Growth Rate by Type in 2016 & 2020
    Figure 37. United States Neurodegenerative Drugs Revenue Share by Application (2016-2021)
    Figure 38. United States Neurodegenerative Drugs Revenue Growth Rate by Application in 2016 & 2020
    Figure 39. North America Neurodegenerative Drugs Sales Growth Rate 2016-2021 (K Units)
    Figure 40. North America Neurodegenerative Drugs Revenue Growth Rate 2016-2021 (US$ Million)
    Figure 41. North America Neurodegenerative Drugs Sales Market Share by Country in 2020
    Figure 42. North America Neurodegenerative Drugs Revenue Market Share by Country in 2020
    Figure 43. United States Neurodegenerative Drugs Sales Growth Rate (2016-2021) (K Units)
    Figure 44. United States Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 45. Canada Neurodegenerative Drugs Sales Growth Rate (2016-2021) (K Units)
    Figure 46. Canada Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 47. Europe Neurodegenerative Drugs Sales Growth Rate 2016-2021 (K Units)
    Figure 48. Europe Neurodegenerative Drugs Revenue Growth Rate 2016-2021 (US$ Million)
    Figure 49. Europe Neurodegenerative Drugs Sales Market Share by Country in 2020
    Figure 50. Europe Neurodegenerative Drugs Revenue Market Share by Country in 2020
    Figure 51. Germany Neurodegenerative Drugs Sales Growth Rate (2016-2021) (K Units)
    Figure 52. Germany Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 53. France Neurodegenerative Drugs Sales Growth Rate (2016-2021) (K Units)
    Figure 54. France Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 55. U.K. Neurodegenerative Drugs Sales Growth Rate (2016-2021) (K Units)
    Figure 56. U.K. Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 57. Italy Neurodegenerative Drugs Sales Growth Rate (2016-2021) (K Units)
    Figure 58. Italy Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 59. Russia Neurodegenerative Drugs Sales Growth Rate (2016-2021) (K Units)
    Figure 60. Russia Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 61. Asia Pacific Neurodegenerative Drugs Sales Growth Rate 2016-2021 (K Units)
    Figure 62. Asia Pacific Neurodegenerative Drugs Revenue Growth Rate 2016-2021 (US$ Million)
    Figure 63. Asia Pacific Neurodegenerative Drugs Sales Market Share by Region in 2020
    Figure 64. Asia Pacific Neurodegenerative Drugs Revenue Market Share by Region in 2020
    Figure 65. China Neurodegenerative Drugs Sales Growth Rate (2016-2021) (K Units)
    Figure 66. China Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 67. Japan Neurodegenerative Drugs Sales Growth Rate (2016-2021) (K Units)
    Figure 68. Japan Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 69. South Korea Neurodegenerative Drugs Sales Growth Rate (2016-2021) (K Units)
    Figure 70. South Korea Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 71. India Neurodegenerative Drugs Sales Growth Rate (2016-2021) (K Units)
    Figure 72. India Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 73. Australia Neurodegenerative Drugs Sales Growth Rate (2016-2021) (K Units)
    Figure 74. Australia Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 75. China Taiwan Neurodegenerative Drugs Sales Growth Rate (2016-2021) (K Units)
    Figure 76. China Taiwan Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 77. Indonesia Neurodegenerative Drugs Sales Growth Rate (2016-2021) (K Units)
    Figure 78. Indonesia Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 79. Thailand Neurodegenerative Drugs Sales Growth Rate (2016-2021) (K Units)
    Figure 80. Thailand Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 81. Malaysia Neurodegenerative Drugs Sales Growth Rate (2016-2021) (K Units)
    Figure 82. Malaysia Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 83. Latin America Neurodegenerative Drugs Sales Growth Rate 2016-2021 (K Units)
    Figure 84. Latin America Neurodegenerative Drugs Revenue Growth Rate 2016-2021 (US$ Million)
    Figure 85. Latin America Neurodegenerative Drugs Sales Market Share by Country in 2020
    Figure 86. Latin America Neurodegenerative Drugs Revenue Market Share by Country in 2020
    Figure 87. Mexico Neurodegenerative Drugs Sales Growth Rate (2016-2021) (K Units)
    Figure 88. Mexico Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 89. Brazil Neurodegenerative Drugs Sales Growth Rate (2016-2021) (K Units)
    Figure 90. Brazil Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 91. Argentina Neurodegenerative Drugs Sales Growth Rate (2016-2021) (K Units)
    Figure 92. Argentina Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 93. Middle East and Africa Neurodegenerative Drugs Sales Growth Rate 2016-2021 (K Units)
    Figure 94. Middle East and Africa Neurodegenerative Drugs Revenue Growth Rate 2016-2021 (US$ Million)
    Figure 95. Middle East and Africa Neurodegenerative Drugs Sales Market Share by Country in 2020
    Figure 96. Middle East and Africa Neurodegenerative Drugs Revenue Market Share by Country in 2020
    Figure 97. Turkey Neurodegenerative Drugs Sales Growth Rate (2016-2021) (K Units)
    Figure 98. Turkey Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 99. Saudi Arabia Neurodegenerative Drugs Sales Growth Rate (2016-2021) (K Units)
    Figure 100. Saudi Arabia Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 101. UAE Neurodegenerative Drugs Sales Growth Rate (2016-2021) (K Units)
    Figure 102. UAE Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
    Figure 103. Neurodegenerative Drugs Value Chain
    Figure 104. Channels of Distribution
    Figure 105. Distributors Profiles
    Figure 106. Bottom-up and Top-down Approaches for This Report
    Figure 107. Data Triangulation
    Figure 108. Key Executives Interviewed
SELECT A FORMAT
Added to Cart

Electronic (PDF)
$3900
This license allows only one user to access the PDF.

Electronic (PDF)
$5850
This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Electronic (PDF)
$7800
This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Nano String

RELATED REPORTS

Global micro bioreactors market reserch report 2021
Global Micro bioreactors market research report 2021

120 Pages
Type: Report
Code: QYRE-Othe-1F481
Tue Oct 26 13:23:37 UTC 2021

Add to Cart

China ELISpot and FluoroSpot Assay Market Report Forecast 2021 2027
China ELISpot and FluoroSpot Assay Market Report & Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-9X7111
Tue Oct 26 00:00:00 UTC 2021

Add to Cart

China Digital PCR DPCR and QPCR Market Report Forecast 2021 2027
China Digital PCR (DPCR) and QPCR Market Report & Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-18O6996
Tue Oct 26 00:00:00 UTC 2021

Add to Cart

Global and United States Pharmaceutical Dryer Market Insights Forecast to 2027
Global and United States Pharmaceutical Dryer Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-25D6747
Mon Oct 25 00:00:00 UTC 2021

Add to Cart